nadofaragene firadenovec shows durable responses in nmibc
Published 4 years ago • 358 plays • Length 0:40Download video MP4
Download video MP3
Similar videos
-
1:41
safety & efficacy of nadofaragene firadenovec for patients with high-grade, bcg unresponsive nmibc
-
1:56
real-world evaluation of nadofaragene firadenovec in bcg-unresponsive nmibc
-
1:19
dr. boorjian on research with nadofaragene firadenovec in nonmuscle invasive bladder cancer
-
1:12
scott tagawa, md, on the study investigating nadofaragene firadenovec in bcg unresponsive nmibc
-
0:15
next-generation immunotherapy for #nmibc #bladdercancer #cancerresearch #cancer #news
-
6:23
pembro monotherapy for participants with bcg–unresponsive hr nmibc shows anti-tumour activity
-
1:59
non muscle invasive bladder cancer (nmibc) overview
-
28:30
high grade non muscle invasive bladder cancer: stages and treatment including bcg
-
16:21
eau24: muscle-invasive and metastatic bladder cancer: new updates in the eau guidelines
-
29:46
introduction to adstiladrin | gene therapy for bcg unresponsive nmibc
-
4:28
very high risk non-muscle-invasive bladder cancer (nmibc) in the current landscape of nmibc
-
7:32
updated envision data: ugn-102 shows 82.3% duration of response in lg-ir-nmibc
-
4:21
bladder preservation, biomarkers for detection, and bcg predictors of response in nmibc
-
15:52
when is radical cystectomy indicated for nmibc?
-
10:35
management of bcg unresponsive cystectomy ineligible bladder cancer patients pembrolizumab
-
43:52
uromigos live 2023: nmibc updates
-
0:31
immunotherapy progress in bladder cancer
-
26:33
questions and answers on adstiladrin | gene therapy for bcg unresponsive nmibc
-
1:05
dr. sonpavde on the role of durvalumab in platinum-refractory bladder cancer
-
1:37
dr. balar on next steps of the keynote-057 trial in nmibc
-
3:31
what is intravesical therapy? | bladder cancer advocacy network
-
3:16
keynote-057 update: pembrolizumab for high-risk nmibc patients